{"id":"W2590244275","doi":"10.1200/jco.2013.31.6_suppl.16","title":"Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Docetaxel; Prostate cancer; Internal medicine; Tolerability; Oncology; Placebo; Androgen receptor; Cancer; Adverse effect; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001098178,0.0004044096,0.001009306,0.000141429,0.0001786629,0.0004308414,0.0002227404,0.0004107831,0.0009636314],"category_scores_gemma":[0.000908952,0.0001139686,0.0009259498,0.0002598049,0.0002091709,0.0003169275,0.0002535823,0.0006584963,0.0001410272],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003462614,"about_ca_system_score_gemma":0.0004242023,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007632847,"about_ca_topic_score_gemma":0.002078228,"domain_scores_codex":[0.9998142,0.00008922465,0.00001817753,0.00002680528,0.0000220279,0.00002944709],"domain_scores_gemma":[0.9994202,0.00009801109,0.0002175969,0.0000299292,0.0000384906,0.0001958395],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7054857,0.006451926,0.1693442,0.001430501,0.005214553,0.0003582454,0.0002319801,0.001389992,0.00619629,0.0001625934,0.004537191,0.0991969],"study_design_scores_gemma":[0.2633358,0.1530636,0.5654244,0.0003635866,0.007270558,0.0008609478,0.000233582,0.00137768,0.001389668,0.0004664582,0.006144018,0.00006967783],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916162,0.006863685,0.00005952837,0.0001997644,0.00004870524,0.00009799661,0.0004775345,0.000007230611,0.0006293253],"genre_scores_gemma":[0.9947733,0.00274604,0.0002298282,0.0004616138,0.0001495312,0.0001575627,0.001098925,0.000003271783,0.0003799472],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001098178,"threshold_uncertainty_score":0.005807757,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09677433790762337,"score_gpt":0.4403547263729814,"score_spread":0.343580388465358,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}